Hepatocellular carcinoma (HCC) has some unique characteristics in the digestive organ cancer. Therefore it is very important to select an appropriate treatment for recurrent HCC according to several situations such as the type of recurrence, previous treatments and conditions of patient. This article is a review of the concept of recurrent multiple HCC and its therapeutic strategies.
[1] S. Shiina, R. Tateishi, T. Arano, et al., “Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors,” American Journal of Gastroenterology, Vol. 107, No. 4, 2012, pp. 569-577. doi:10.1038/ajg.2011.425
[2] H. Imamura, Y. Matsuyama, E. Tanaka, et al., “Risk Factors Contributing to Early and Late Phase Intrahepatic Recurrence of Hepatocellular Carcinoma after Hepatectomy,” Journal of Hepatology, Vol. 38, No. 2, 2003, pp. 200-207. doi:10.1016/S0168-8278(02)00360-4
[3] M. Kudo, et al., “Report of the 18th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan,” Kanzo (in Japanese), Vol. 51, No. 8, 2010, pp. 460-484.
[4] T. Ishikawa, K. Higuchi, T. Kubota, et al., “Combination PEG-IFN-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma Is Capable of Improving Hepatic Functional Reserve and Survival,” Hepatogastroenterology, Vol. 59, No. 114, 2012, pp. 529-532. doi:10.5754/hge10867
[5] N. Kokudo and M. Makuuchi, “Evidence-Based Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan: The J-HCC Guidelines,” Journal of Gastroenterology, Vol. 44, No. 19, 2009, pp. 119-121. doi:10.1007/s00535-008-2244-z
[6] M. Kudo, N. Izumi, N. Kokudo, HCC Expert Panel of Japan Society of Hepatology, et al., “Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version,” Digestive Diseases, Vol. 29, No. 3, 2011, pp. 339-364. doi:10.1159/000327577
[7] S. Togo, K. Tanaka, H. Masui, et al., “Usefulness of Prophylactic Transcatheter Arterial Infusion of Anticancer Agents with Lipiodol to Prevent Recurrence of Hepatocellular Carcinoma after Hepatic Resection,” International Surgery, Vol. 90, No. 2, 2005, pp. 103-108.
[8] M. Satake, H. Uchida, Y. Arai, et al., Transcatheter Arterial Chemoembolization (TACE) with Lipiodol to Treat Hepatocellular Carcinoma: Survey Results from the TACE Study Group of Japan,” CardioVascular and Interventional Radiology, Vol. 31, No. 4, 2008, pp. 756-761. doi:10.1007/s00270-007-9255-7
[9] K. Takayasu, S. Arii, I. Ikai, Liver Cancer Study Group of Japan, et al., “Overall Survival after Transarterial Lipiodol Infusion Chemotherapy with or without Embolization for Unresectable Hepatocellular Carcinoma: Propensity Score Analysis,” American Journal of Roentgenology, Vol. 194, No. 3, 2010, pp. 830-837. doi:10.2214/AJR.09.3308
[10] H. Yodono, K. Matsuo and A. Shinohara, “A Retrospective Comparative Study of Epirubicin-Lipiodol Emulsion and Cisplatin-Lipiodol Suspension for Use with Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma,” Anticancer Drugs, Vol. 22, No. 3, 2011, pp. 277-282. doi:10.1097/CAD.0b013e328342231d
[11] K. Kasai, A. Ushio, K. Sawara, et al., “Transcatheter Arterial Chemoembolization with a Fine-Powder Formulation of Cisplatin for Hepatocellular Carcinoma,” World Journal of Gastroenterology, Vol. 16, No. 27, 2010, pp. 3437-3444. doi:10.3748/wjg.v16.i27.3437
[12] ACE500 Study. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows &type=summary&recptno=R000001678&language=E
[13] M. Ikeda, Y. Arai, et al., “Transcatheter Arterial Chemoembolization with Epirubicin and Lipiodol for Unresectable Hepatocellular Carcinoma-Subgroup Analysis of Japanese Patients in Cooperative Study between Korea and Japan,” Japanese Journal of Radiology, Vol. 27, 2012, pp. 299-304.
[14] K. Yamakado, S. Miyayama, S. Hirota, et al., “Hepatic Arterial Embolization for Unresectable Hepatocellular Carcinomas: Do Technical Factors Affect Prognosis?” Japanese Journal of Interventional Radiology, Vol. 30, No. 7, 2012, pp. 560-566. doi:10.1007/s11604-012-0088-1
[15] K. Osuga, Y. Arai, H. Anai, et al., “Phase I/II Multicenter Study of Transarterial Chemoembolization with a Cisplatin Fine Powder and Porous Gelatin Particles for Unresectable Hepatocellular Carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401,” Journal of Vascular and Interventional Radiology, Vol. 23, No. 10, 2012, pp. 1278-1285. doi:10.1016/j.jvir.2012.06.028
[16] T. Ishikawa, K. Higuchi, T. Kubota, et al., “Prevention of Intrahepatic Distant Recurrence by Transcatheter Arterial Infusion Chemotherapy with Platinum Agents for Stage I/II Hepatocellular Carcinoma,” Cancer, Vol. 117, No. 17, 2011, pp. 4018-4025. doi:10.1002/cncr.25989
[17] J. Bruix and M. Sherman, “American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update,” Hepatology, Vol. 53, No. 3, 2011, pp. 1020-1022. doi:10.1002/hep.24199
[18] T. Ishikawa, M. Imai, H. Kamimura, et al., “Improved Survival for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Intra-Arterial Chemotherapy Combining Etoposide, Carboplatin, Epirubicin and Pharmacokinetic Modulating Chemotherapy by 5-FU and Enteric-Coated Tegafur/Uracil: A Pilot Study,” World Journal of Gastroenterology, Vol. 13, No. 41, 2007, pp. 5465-5470.
[19] T. Ishikawa, “Future Perspectives on the Treatment of Hepatocellular Carcinoma with Cisplatin,” World Journal of Hepatology, Vol. 1, No. 1, 2009, pp. 8-16. doi:10.4254/wjh.v1.i1.8